article thumbnail

Synlogic gets grant for genetically engineered bacteria for attenuating metabolic diseases

Pharmaceutical Technology

Discover how Synlogic Inc's patented genetically engineered bacteria produce short-chain fatty acids to combat metabolic diseases. Learn more about this innovative treatment approach.

article thumbnail

Yield10 Bioscience gets grant for genetically engineered oilseed plant expressing plant protein

Pharmaceutical Technology

Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cellectis files patent for engineered T-cells for immunotherapy with inhibited B2M expression

Pharmaceutical Technology

Discover Cellectis SA's groundbreaking patent for engineered T-cells designed for immunotherapy, targeting cancer, infections, and autoimmune diseases. Learn about the innovative method and composition outlined in the patent for effective and affordable treatment.

Engineer 130
article thumbnail

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

Pharmaceutical Technology

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. The post Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run appeared first on Pharmaceutical Technology.

Engineer 262
article thumbnail

World’s first engineered B cell therapy enters human trials

Drug Discovery World

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Immusoft is advancing the world’s first engineered B cell therapy, which may have significant impact for patients with this rare disease and potentially many others.

Engineer 113
article thumbnail

Ginkgo buys StrideBio’s AAV discovery and engineering platform assets

Pharmaceutical Technology

Ginkgo Bioworks has strengthened its end-to-end R&D capabilities in gene therapy with the purchase of adeno-associated virus (AAV) capsid discovery and engineering assets from StrideBio, for an undisclosed sum. As part of the transaction, one StrideBio employee will be transferred to Ginkgo’s mammalian engineering team.

Engineer 130
article thumbnail

Making Sense of Engineering Titles in Biopharma

BioSpace

Engineers help their employers remain efficient, GMP-compliant and up-to-date on the latest technologies and industry trends.

Engineer 113